Covid-19 Oral Antiviral MK-4482 (molnupiravir)
Contract Overview
Contract Amount: $2,205,000,834 ($2.2B)
Contractor: Merck Sharp & Dohme LLC
Awarding Agency: Department of Defense
Start Date: 2021-06-07
End Date: 2023-07-13
Contract Duration: 766 days
Daily Burn Rate: $2.9M/day
Official Description: COVID-19 ORAL ANTIVIRAL MK-4482 (MOLNUPIRAVIR)
Place of Performance
Location: New Jersey, 07033